BSFA Overzicht aandelen ANI Pharmaceuticals, Inc., een biofarmaceutisch bedrijf, ontwikkelt, produceert en verkoopt merkgeneesmiddelen en generieke geneesmiddelen op recept in de Verenigde Staten en Canada. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
ANI Pharmaceuticals, Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor ANI Pharmaceuticals Historische aandelenkoersen Huidige aandelenkoers US$55.50 52 Week Hoogtepunt US$64.00 52 Week Laag US$47.80 Bèta 0.74 1 maand verandering 4.72% 3 maanden verandering 4.72% 1 Jaar Verandering 8.82% 3 jaar verandering 70.25% 5 jaar verandering -5.13% Verandering sinds IPO 1,069.16%
Recent nieuws en updates
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 Jan 13
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity Jan 02
Senior VP of Finance & CFO recently sold €399k worth of stock Dec 19
President recently sold €194k worth of stock Nov 29
Senior Vp & Head of Rare Disease recently sold €356k worth of stock Nov 19
Third quarter 2024 earnings released: US$1.27 loss per share (vs US$0.46 profit in 3Q 2023) Nov 09 Meer updates bekijken
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 Jan 13
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity Jan 02
Senior VP of Finance & CFO recently sold €399k worth of stock Dec 19
President recently sold €194k worth of stock Nov 29
Senior Vp & Head of Rare Disease recently sold €356k worth of stock Nov 19
Third quarter 2024 earnings released: US$1.27 loss per share (vs US$0.46 profit in 3Q 2023) Nov 09
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024 Nov 08
ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 31
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06% Oct 25
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others. Sep 17 Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement Sep 11
Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.30 profit in 2Q 2023) Aug 07
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024 Aug 06
ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder Jul 15
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index Jul 03
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP Jul 02 ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million. Jun 25
Senior VP of Finance & CFO recently sold €292k worth of stock Jun 09
President recently sold €1.0m worth of stock May 17
ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 11
First quarter 2024 earnings released: EPS: US$0.93 (vs US$0.056 in 1Q 2023) May 10
ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024 Apr 20
ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension Apr 10
ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024 Apr 06
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP Mar 27
Independent Director recently sold €420k worth of stock Mar 08
Full year 2023 earnings released: EPS: US$0.95 (vs US$3.05 loss in FY 2022) Mar 01
ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Feb 29
ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024 Feb 08
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP Jan 24
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP Jan 16
Head of Rare Disease recently sold €148k worth of stock Nov 14
New minor risk - Share price stability Nov 10
Third quarter 2023 earnings released: EPS: US$0.51 (vs US$0.55 loss in 3Q 2022) Nov 09
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023 Nov 09
ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares Oct 05
Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1% Aug 29
ANI Pharmaceuticals, Inc. Announces Board Changes Aug 24
President recently sold €3.0m worth of stock Aug 17
Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.94 loss in 2Q 2022) Aug 10
Forecast breakeven date moved forward to 2023 Aug 10
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023 Aug 10
ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 01
New minor risk - Profitability Jul 24 ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million. May 13
First quarter 2023 earnings released: EPS: US$0.063 (vs US$1.27 loss in 1Q 2022) May 09 ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023
Full year 2022 earnings released: US$3.05 loss per share (vs US$3.40 loss in FY 2021) Mar 10
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP Dec 20
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP Nov 29
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP Nov 17
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.37 loss in 3Q 2021) Nov 10
Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022 Nov 10
ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 25
ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer Sep 13
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP Aug 30
Key Executive recently sold €661k worth of stock Aug 18
ANI Pharmaceuticals, Inc. Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP Aug 17 ANI Pharmaceuticals, Inc. Reports Impairment Charge for the Second Quarter Ended June 30, 2022
Second quarter 2022 earnings released: US$0.94 loss per share (vs US$1.17 loss in 2Q 2021) Aug 08
Ani Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP Aug 04
ANI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary Jul 19
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP Jun 02
ANI Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022 May 12
First quarter 2022 earnings released: US$1.27 loss per share (vs US$0.007 profit in 1Q 2021) May 10
High number of new directors Apr 27
ANI Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022 Apr 20
ANI Pharmaceuticals, Inc. Announces the Launch of Misoprostol Tablets Apr 12
Chairman recently bought €126k worth of stock Mar 23
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 16
ANI Pharmaceuticals Announces Executive Changes Feb 25
ANI Pharmaceuticals, Inc., Annual General Meeting, Apr 27, 2022 Feb 16
Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® Powder, Including 180 Days of Exclusivity Feb 15
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel for Multiple Chronic Autoimmune Disorders Jan 25
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP Dec 22
Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc Announce Commercial Availability of Carglumic Acid Tablets Dec 21
Independent Director recently bought €87k worth of stock Dec 08
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Novitium Pharma LLC. Nov 24
ANI Pharmaceuticals, Inc. announced that it has received $25 million in funding from Ampersand Management LLC Nov 23
Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.035 profit in 3Q 2020) Nov 04
ANI Pharmaceuticals, Inc. Announces Launch of Nebivolol Tablets Sep 20
Ani Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome Sep 02
Second quarter 2021 earnings released: US$1.17 loss per share (vs US$1.03 loss in 2Q 2020) Aug 08 ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Growth Index
First quarter 2021 earnings released: EPS US$0.007 (vs US$0.59 loss in 1Q 2020) May 08 Rendement voor aandeelhouders BSFA DE Pharmaceuticals DE Markt 7D 1.8% 1.5% 1.9% 1Y 8.8% -7.6% 15.1%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: BSFA overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -7.6 % opleverde.
Rendement versus markt: BSFA presteerde slechter dan German Market , dat het afgelopen jaar een rendement van 15.1 % opleverde.
Prijsvolatiliteit Is BSFA's price volatile compared to industry and market? BSFA volatility BSFA Average Weekly Movement 4.6% Pharmaceuticals Industry Average Movement 5.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stabiele aandelenkoers: BSFA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de German markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van BSFA is het afgelopen jaar stabiel geweest.
Over het bedrijf ANI Pharmaceuticals, Inc., een biofarmaceutisch bedrijf, ontwikkelt, produceert en verkoopt merkgeneesmiddelen en generieke geneesmiddelen op recept in de Verenigde Staten en Canada. Het bedrijf produceert producten in vaste vorm voor oraal gebruik, halfvaste, vloeibare en topicale toediening, gereguleerde stoffen en krachtige producten, evenals contractontwikkeling en productie van farmaceutische producten. Het verkoopt zijn producten via apotheekketens, groothandelaren, distributeurs en postorderapotheken, collectieve inkooporganisaties, gespecialiseerde apotheken en ziekenhuizen.
Meer tonen ANI Pharmaceuticals, Inc. Samenvatting Hoe verhouden de winst en inkomsten van ANI Pharmaceuticals zich tot de beurswaarde? BSFA fundamentele statistieken Marktkapitalisatie €1.10b Inkomsten(TTM ) -€8.46m Inkomsten(TTM ) €535.85m
2.1x P/S-verhouding
-130.6x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) BSFA resultatenrekening (TTM ) Inkomsten US$555.46m Kosten van inkomsten US$223.35m Brutowinst US$332.11m Overige uitgaven US$340.87m Inkomsten -US$8.77m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.45 Brutomarge 59.79% Nettowinstmarge -1.58% Schuld/Eigen Vermogen Verhouding 145.2%
Hoe presteerde BSFA op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/02/01 04:02 Aandelenkoers aan het einde van de dag 2025/01/31 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten ANI Pharmaceuticals, Inc. wordt gevolgd door 13 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Dewey Steadman Canaccord Genuity Louise Chen Cantor Fitzgerald & Co. Timothy Chiang Capital One Securities, Inc.
Toon 10 meer analisten 
